These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 11336056)

  • 1. Upper gastrointestinal toxicity of rofecoxib and naproxen.
    Delgado Fernández M; Zambrana García JL; Diez García F
    N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336056
    [No Abstract]   [Full Text] [Related]  

  • 2. [Coxib instead of NSAID plus gastric acid inhibitor. Protection for the small intestine].
    MMW Fortschr Med; 2004 Mar; 146(13):61. PubMed ID: 15219139
    [No Abstract]   [Full Text] [Related]  

  • 3. [Prevention of ulcer lesions under non-steroid antirheumatic agents. For each patient the appropriate stomach protection].
    MMW Fortschr Med; 2004 May; 146(22):48. PubMed ID: 15373113
    [No Abstract]   [Full Text] [Related]  

  • 4. Review article: prevention of non-steroidal anti-inflammatory drug gastrointestinal complications--review and recommendations based on risk assessment.
    Chan FK; Graham DY
    Aliment Pharmacol Ther; 2004 May; 19(10):1051-61. PubMed ID: 15142194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upper gastrointestinal toxicity of rofecoxib and naproxen.
    Gupta S
    N Engl J Med; 2001 May; 344(18):1398; author reply 1398-9. PubMed ID: 11336057
    [No Abstract]   [Full Text] [Related]  

  • 6. Therapies for ulcers associated with nonsteroidal antiinflammatory drugs.
    Chan FK; Sung JJ
    N Engl J Med; 1998 Jul; 339(5):349-50; author reply 350-1. PubMed ID: 9696650
    [No Abstract]   [Full Text] [Related]  

  • 7. Risk factors associated with the development of gastroduodenal ulcers due to the use of NSAIDs.
    Wolfe MM
    Int J Clin Pract Suppl; 2003 Apr; (135):32-7. PubMed ID: 12723745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing clinically significant gastrointestinal toxicity associated with nonsteroidal antiinflammatory drugs.
    Jacobsen RB; Phillips BB
    Ann Pharmacother; 2004 Sep; 38(9):1469-81. PubMed ID: 15213313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medical treatment of stomach ulcer except in emergency].
    Bretagne JF
    Gastroenterol Clin Biol; 1996 Jan; 20(1 Pt 2):S73-S80. PubMed ID: 8734374
    [No Abstract]   [Full Text] [Related]  

  • 10. Is rofecoxib safer than naproxen?
    Adelman A
    J Fam Pract; 2001 Mar; 50(3):204. PubMed ID: 11252204
    [No Abstract]   [Full Text] [Related]  

  • 11. Rofecoxib-associated upper gastrointestinal bleed: a case report.
    Freedman GM; Kreitzer JM; Badola R
    Mt Sinai J Med; 2002; 69(1-2):105-6. PubMed ID: 11832981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Underutilization of preventive strategies in patients receiving NSAIDs.
    Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
    Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Upper gastrointestinal complications related to non-steroidal anti-inflammatory drugs--what have we achieved so far?
    Wong VW; Leong RW; Chan FK
    Dig Liver Dis; 2004 Jan; 36(1):1-3. PubMed ID: 14971808
    [No Abstract]   [Full Text] [Related]  

  • 14. Celecoxib compared with lansoprazole and naproxen to prevent gastrointestinal ulcer complications.
    Lai KC; Chu KM; Hui WM; Wong BC; Hu WH; Wong WM; Chan AO; Wong J; Lam SK
    Am J Med; 2005 Nov; 118(11):1271-8. PubMed ID: 16271912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The management of upper gastrointestinal problems in patients taking NSAIDs.
    Prichard P
    Aust Fam Physician; 1991 Dec; 20(12):1739-41. PubMed ID: 1687198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ulcer recurrence in high-risk patients receiving nonsteroidalanti-inflammatory drugs plus low-dose aspirin: results of a post HOC subanalysis.
    Goldstein JL; Huang B; Amer F; Christopoulos NG
    Clin Ther; 2004 Oct; 26(10):1637-43. PubMed ID: 15598480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A patient with high risk of gastrointestinal bleeding requiring nonsteroidal anti-inflammatory drugs.
    Wilcox CM; Ladabaum U
    Clin Gastroenterol Hepatol; 2006 Sep; 4(9):1090-3. PubMed ID: 16890026
    [No Abstract]   [Full Text] [Related]  

  • 18. Risks and benefits of COX-2 inhibitors vs non-selective NSAIDs: does their cardiovascular risk exceed their gastrointestinal benefit? A retrospective cohort study.
    Rahme E; Nedjar H
    Rheumatology (Oxford); 2007 Mar; 46(3):435-8. PubMed ID: 17255138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of NSAID-gastropathy.
    Ardizzone S; Bianchi Porro G
    Ital J Gastroenterol; 1996 Dec; 28 Suppl 4():33-6. PubMed ID: 9032581
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK; Seeger JD; Kuntz KM
    Am J Med; 2004 May; 116(9):621-9. PubMed ID: 15093759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.